Skip to main content
Clinical Trials/NCT03132168
NCT03132168
Completed
Not Applicable

Postoperative Delirium in Patients Undergoing Radical Cystectomy

Ohio State University1 site in 1 country50 target enrollmentJanuary 10, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post-operative Delirium
Sponsor
Ohio State University
Enrollment
50
Locations
1
Primary Endpoint
Post-operative delirium
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

In this study, post-operative delirium will be measured in patients undergoing surgery for bladder resection, and associated microRNA biomarkers will be evaluated in patients considered delirious and non-delirious after surgery.

Detailed Description

With voluntary participation, this study requires participants to complete a self-administered cognitive evaluation (SAGE) before surgery to assess baseline cognitive impairment and early dementia; vital signs will be documented prior to surgery. During surgery, participants will receive a standardized general anesthesia regimen as described in the protocol. Several parameters will be measured during surgery, including bispectral monitoring to measure processed EEG. After surgery, fitness for cognitive evaluation will be determined by the Richmond Agitation-Sedation Scale (RASS) scale, and then emergence delirium will be assessed using the CAM-ICU scale. Fitness for discharge from PACU will be determined by an Aldrete score of 9 or more. Postoperative pain will be assessed using the 11-point Numeric Rating Scale (NRS-11). Postoperative nausea and vomiting (PONV) level will also be documented. Postoperative Delirium (POD) assessment will be achieved by administering the memorial delirium assessment scale (MDAS) twice a day starting on day 1 through day 3 postoperatively. Pain NRS-11 score and PONV levels will also be documented at each visit. For microRNA testing, blood probes will be collected in 5mL purple top tube at surgical preadmission and post-surgery days one, two and three. Risks associated with participating in this study include normal risk associated with having surgery and general anesthesia; no greater than minimal risk is associated with blood collection. For the participant, there are no immediate anticipated benefits for participating in this study. The importance of the knowledge that is expected to result includes lower post-operative complications as a result of post-operative delirium, faster recovery, and shorter hospital stay.

Registry
clinicaltrials.gov
Start Date
January 10, 2018
End Date
January 31, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ahmad Shabsigh

Assistant Professor

Ohio State University

Eligibility Criteria

Inclusion Criteria

  • Male or female, 18 years of age and older
  • ASA II or III
  • Capable of and willing to consent
  • Participants literate in English language

Exclusion Criteria

  • ASA IV or V
  • Patients with severe visual or auditory impairment
  • Inability to read and/or write in English
  • Presence of a clinically diagnosed major psychiatric condition such as bipolar disorder, uncontrolled major depression, schizophrenia
  • Dementia of Alzheimer's type
  • Parkinson's disease
  • Multiple Sclerosis (MS)
  • Vascular dementia

Outcomes

Primary Outcomes

Post-operative delirium

Time Frame: up to 3 days post-operatively

Evaluate the incidence of and risk factors for POD in patients undergoing radical cystectomy utilizing the Memorial Delirium Assessment Scale.

Secondary Outcomes

  • microRNA expression(up to 3 days post-operatively)

Study Sites (1)

Loading locations...

Similar Trials